Pharmacokinetic Properties of Sulfadoxine-Pyrimethamine in Pregnant Women
Harin A Karunajeewa, Sam Salman, Ivo Mueller, Francisca Baiwog, Servina Gomorrai, Irwin Law, Madhu Page-Sharp, Stephen Rogerson, Peter Siba, Kenneth F Ilett, Timothy ME Davis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | AMER SOC MICROBIOLOGY | Published : 2009
To determine the pharmacokinetic disposition of sulfadoxine (SDOX) and pyrimethamine (PYR) when administered as intermittent presumptive treatment during pregnancy (IPTp) for malaria, 30 Papua New Guinean women in the second or third trimester of pregnancy and 30 age-matched nonpregnant women were given a single dose of 1,500 mg of SDOX plus 75 mg of pyrimethamine PYR. Blood was taken at baseline and 1, 2, 4, 6, 12, 18, 24, 30, 48, and 72 h and at 7, 10, 14, 28, and 42 days posttreatment in all women. Plasma samples were assayed for SDOX, N-acetylsulfadoxine (NASDOX), and PYR by high-performance liquid chromatography. Population pharmacokinetic modeling was performed using NONMEM v6.2.0. Sep..View full abstract
Awarded by National Health and Medical Research Council
We are most grateful to Sr. Valsi Kurian and the staff of Alexishafen Health Centre for their kind cooperation during the study. We also thank Jovitha Lammey, Maria Goretti, Wesley Sikuma, Donald Paiva, and Bernard ("Ben") Maamu for clinical and/or logistic assistance.This study was funded by the National Health and Medical Research Council of Australia (grant 458555). T. M. E. D. is supported by a National Health and Medical Research Council of Australia Practitioner Fellowship.